[1] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018, 69(2): 406-460.
[2] Deltenre P, Zanetto A, Saltini D, et al. The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: Recent evolution and open questions. Hepatol, 2023, 77(2): 640-658.
[3] Engelmann C, Clària J, Szabo G, et al. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol, 2021, 75(Suppl 1): S49-66.
[4] Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut, 2021, 70(1): 9-29.
[5] Izzy M, VanWagner LB, Lin G, et al. Redefining cirrhotic cardiomyopathy for the modern era. Hepatol, 2020,71(1): 334-345.
[6] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII-renewing consensus in portal hypertension. J Hepatol, 2022, 76(4): 959-974.
[7] Bettinger D, Thimme R, Schultheiss M. Implantation of transjugular intrahepatic portosystemic shunt (TIPS): indication and patient selection. Curr Opin Gastroenterol, 2022, 38(3): 221-229.
[8] Bosch J. Small diameter shunts should lead to safe expansion of the use of TIPS. J Hepatol, 2021, 74(1): 230-234.
[9] Horhat A, Bureau C, Thabut D, et al. Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: indications and posttransjugular intrahepatic portosystemic shunt complications in 2020. United European Gastroenterol J, 2021, 9(2): 203-208.
[10] Caporali C, Turco L, Prampolini F, et al. Proximal splenic artery embolization to treat refractory ascites in a patient with cirrhosis. Hepatol, 2021, 74(6): 3534-3538.
[11] Billey C, Billet S, Robic MA, et al. A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: the Toulouse algorithm. Hepatol, 2019, 70(6): 1928-1941.
[12] Boike JR, Thornburg BG, Asrani SK, et al. North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clin Gastroenterol Hepatol, 2022, 20(8): 1636-1662.e36.
[13] Bettinger D, Sturm L, Pfaff L, et al. Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. J Hepatol, 2021, 74(6): 1362-1372.
[14] 中华医学会消化病学分会微创介入协作组. 经颈静脉肝内门体静脉分流术治疗门静脉高压专家共识(2022年版). 中华肝脏病杂志, 2022, 30(12): 1349-1364.
[15] Lai JC, Tandon P, Bernal W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatol, 2021, 74(3): 1611-1644.
[16] Rose CF, Amodio P, Bajaj JS, et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol, 2020, 73(6): 1526-1547.
[17] Italian Association for the Study of the Liver. Portal hypertension and ascites: patient-and population-centered clinical practice guidelines by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis, 2021, 53(9): 1089-1104.
[18] Bureau C, Métivier S, D'Amico M, et al. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol, 2011, 54(5): 901-907.
[19] Li J, Tang S, Zhao J, et al. Long-term survival prediction for transjugular intrahepatic portosystemic shunt in severe cirrhotic ascites: assessment of ten prognostic models. Eur J Gastroenterol Hepatol, 2021, 33(12): 1547-1555.
[20] Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatol, 2021, 74(2): 1014-1048. |
